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ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is a common cancer diagnosis 
worldwide. Despite advances in treatment, HNSCC has very poor survival outcomes, 
emphasizing an ongoing need for development of improved therapeutic options. 
The distinct tumor characteristics of human papillomavirus (HPV)-positive vs. 
HPV-negative disease necessitate development of treatment strategies tailored 
to tumor HPV-status. High-throughput robotic screening of 1,433 biologically and 
pharmacologically relevant compounds at a single dose (4 μM) was carried out against 
6 HPV-positive and 20 HPV-negative HNSCC cell lines for preliminary identification 
of therapeutically relevant compounds. Statistical analysis was further carried out 
to differentiate compounds with preferential activity against cell lines stratified by 
the HPV-status. These analyses yielded 57 compounds with higher activity in HPV-
negative cell lines, and 34 with higher-activity in HPV-positive ones. Multi-point 
dose-response curves were generated for six of these compounds (Ryuvidine, MK-
1775, SNS-032, Flavopiridol, AZD-7762 and ARP-101), confirming Ryuvidine to have 
preferential potency against HPV-negative cell lines, and MK-1775 to have preferential 
potency against HPV-positive cell lines. These data comprise a valuable resource for 
further investigation of compounds with therapeutic potential in the HNSCC.
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INTRODUCTION
There has been an epidemic rise in oropharyngeal 
cancer worldwide due to increasing rates of oral infection 
with human papillomavirus (HPV) [1, 2]. HPV-positive 
cancers typically arise in younger and healthier patients 
that consume less alcohol and tobacco than patients with 
HPV-negative head and neck squamous cell cancers 
(HNSCC). Although HPV-positive patients are much 
more likely to be cured of their disease [1, 3], an important 
challenge for these patients has been enduring the acute 
and chronic toxicities of therapy. In addition, HPV-positive 
tumors are distinct from a molecular perspective, with 
characteristic genetic, epigenetic and protein profiles [4]. 
Given these profound differences between HPV-positive 
and HPV-negative disease at the clinical and molecular 
level, it is logical that the development of any therapy is 
tailored specifically for the tumor HPV-status.
Cell lines are imperfect models of cancer [5, 6], 
however HNSCC cell lines appear to have a similar 
genomic landscape to primary tumors [7, 8]. More 
importantly, genomic markers of drug sensitivity in cell 
lines appear to generally correlate well with validated 
biomarkers in patient tumors [7, 9]. Thus, as cell lines 
can be easily and cheaply screened with large collections 
of drugs, they are invaluable tools to identify new agents 
with potent activity against tumor cells.
This study aimed to carry out a high-throughput 
drug screen of a large collection of compounds against 
HNSCC cell lines, with the objective of preliminary 
identification of potent and HPV-status selective agents 
suitable for further investigation.
RESULTS
High-throughput screening identified multiple 
drugs with high potency against HNSCC cell 
lines
The top 20 compounds with the highest activity 
from the kinase inhibitor and Tocris panels are reported 
in Figure 1A and 1B, respectively (List of compounds and 
mechanism of action can be found in Supplementary Table 
1). This screen identified drugs with high potency that 
included a diverse range of chemotherapeutic and targeted 
agents, however several themes emerged (Supplementary 
Figure 1). Four inhibitors of the phosphoinositide 3 
kinase (PI3K) pathway were identified (GDC0941, PIK-
75, NVP-BEZ235, FAK Inhibitor 14), as were 3 drugs 
reported to affect various aspect of the cell cycle (MK 
1775, TCS2312, NSC 146109). Three topoisomerase 
inhibitors were potent (Daunorubicin, Doxorubicin and 
SN 38). Multiple compounds affecting inflammatory 
pathways through inhibition of proteins such as NF-
κB, IKKβ and IκBα were also identified (IMD0354, 
Pyrrolidinedithiocarbamate ammonium, MG 132 and Bay 
11-7085). Cisplatin and carboplatin, chemotherapeutics 
in routine use head and neck cancer, did not meet our 
criteria for significant activity (B-score < -2) in the cell 
line panel at a dose of 4μM (Supplementary Figure 2). 
Complete tables of individual compound activity against 
each cell line from the kinase inhibitor and Tocris panels 
are provided in Supplementary Table 2.
A subset of compounds demonstrated 
preferential activity against cell lines based on 
HPV-status
Thirty compounds from the kinase panel, and 27 
compounds from the Tocris panel were found to be more 
potent against HPV-positive cell lines (Figure 2A shows 
top hits, full list in Supplementary Table 3). Among the 
identified hits, multiple compounds impacted cell cycle 
pathways (Supplementary Figure 1), including inhibition 
of cyclin-dependent kinases (CDK: SNS-032, Alvocidib), 
PI3K (PI-103, PIK90, Deguelin), polo-like kinase 1 
(PLK1: GSK-461364, BI 2536), and checkpoint kinases 
(CHK: AZD-7762, SB 218078). Various Janus kinase 
(JAK) inhibitors were also seen in the HPV-positive 
preferential list (AZ-960, Merck-5, AT9283, Lestaurtinib). 
The compounds DIPPA hydrochloride, MVC 05-290, Way 
629, Physostigmine and PNC 120596 that are known to 
act on neuro-receptors were demonstrated to be more 
potent in the HPV-positive cell lines.
Six compounds from the kinase inhibitor panel 
and 28 compounds from the Tocris panel were found to 
have higher activity in HPV-negative cell lines (Figure 
2B shows top hits, full list in Supplementary Table 
4). Three compounds impacting cellular proliferation 
and differentiation were identified (Supplementary 
Figure 1), including SB-505124, focal adhesion kinase 
(FAK) Inhibitor 14 and Aminopurvalanol A. From the 
Tocris panel, compounds impacting various aspects 
of cellular regulation and physiology were common 
hits against HPV-negative cell lines (Supplementary 
Figure 1), including Y-26763, D-AP7, BADGE, SKF 
96365 hydrochloride, Olvanil, Embelin, GR 127935 
hydrochloride, Demethylasterriquinone B1, Tyrphostin 
B44, Ro 90-7501, PALDA and OLDA.
Dose response curves confirm Ryuvidine and 
MK-1775 to be preferentially potent against 
HPV-negative and positive cell lines respectively
After the generation of multi-point dose response 
curves, Ryuvidine was selectively potent against HPV-
negative cell lines, with an average IC50 of 1.562 μM ± 
0.755 (mean ± standard deviation) in HPV-negative and 
3.169 μM ± 1.305 in HPV-positive cell lines (Figure 3A, 
unpaired t-test p=0.003), confirming the findings in the 
high-throughput screen. MK-1775 showed significantly 
higher potency against HPV-positive cell lines with 
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an average IC50 of 0.535 μM ± 0.4828 in HPV-positive 
and 3.647 μM ± 3.73 in HPV-negative cell lines (Figure 
3B, unpaired t-test p=0.03), again showing compatible 
findings with the high-throughput drug screen. SNS-032, 
Flavopiridol, AZD-7762 and ARP-101 compounds did not 
show significantly different potency in cell lines stratified 
by HPV-status following validation studies across a range 
of concentrations (Supplementary Figure 3, unpaired t-test 
p>0.05). Dose-response studies of MK-1775, Ryuvidine, 
AZD7762 and Flavopiridol in control non-cancerous 
IMR90 cell line showed higher IC50 values (IC50 of 
>10 μM, 2.2 μM, 0.61 μM and >10 μM, respectively) 
compared to susceptible HNSCC cell lines, demonstrating 
the presence of a therapeutic window.
DISCUSSION
To our knowledge, this is the first high-throughput 
drug screening study that focuses specifically on head 
and neck cancer cell lines. Our study of 1,433 compounds 
in 26 cell lines identified 57 and 34 compounds with 
preferential activity against HPV-negative and HPV-
positive cell lines, respectively. Validation studies with 
six of these confirmed selective potencies in HPV-
Figure 1: The top 20 most potent drugs and determined by the B-score in HNSCC cell lines from the Kinase inhibitor (A) 
and Tocris (B) panels in the high-throughput drug screen.
Oncotarget26067www.oncotarget.com
negative (Ryuvidine) and HPV-positive (MK-1775) cell 
lines. Given that HPV-positive and negative tumors are 
distinct from a molecular and prognostic perspective [10], 
this first step in the development of therapeutics specific 
to each disease type is critical to achieve the end goal of 
maximizing survival rates while minimizing toxicity.
Multiple studies and clinical trials have identified 
a superior response to chemotherapy, and better survival 
outcomes in HPV-positive HNSCCs compared to the 
HPV-negative tumors [3, 11–14]. Following these 
observations, treatment plans and clinical trials for 
HNSCC are increasingly being tailored based on tumor 
HPV status, particularly with the aim to de-intensify 
treatment for patients with HPV-positive tumors [15]. It 
is notable that despite the overall favourable outcomes in 
HPV-positive tumors, treatment failure still occurs in 20-
Figure 2: Top 10 drugs with (A) HPV-positive and (B) HPV-negative selective potency from Kinase inhibitor and Tocris compound 
panels.
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40% of advanced disease [16]. As a result, there remains 
a necessity for further discovery and development of 
selective therapeutics in both HPV-positive and negative 
cohorts of HNSCCs.
Ryuvidine functions as an inhibitor of the CDK4 
and SETD8 proteins [17, 18]. CDK4, and its close relative 
CDK6, interact with cyclin D and function in a pathway 
that is important for cell cycle progression. The CDK4/
cyclin D complex impacts cell cycle progression by 
phosphorylating and inactivating retinoblastoma (Rb), a 
negative regulator of G1 exit [19]. Interestingly, Cyclin D1 
is amplified frequently in HPV-negative HNSCC and p16, 
the negative regulator of the kinase complex, is frequently 
deleted [20]. Thus, Ryuvidine may reverse the effects 
of these mutations, leading to cell cycle arrest in HPV-
negative HNSCC. In contrast, the Rb pathway is abrogated 
in HPV-positive cells as the HPV E7 oncoprotein binds Rb 
and targets it for degradation [21]. Thus, the drug would 
not be expected to have an effect in HPV-positive cells, 
which is consistent with our finding (Figure 3A). Further 
investigation will be required to clarify the mechanism 
behind the observed preferential potency of Ryuvidine 
against HPV-negative cell lines.
MK-1775, also known as AZD1775, is a WEE1 
kinase inhibitor [22]. WEE1 kinase has been linked to G2-M 
cell cycle arrest in response to DNA damage. Inhibition of 
WEE1 kinase can therefore overcome G2 cell cycle arrest, 
which in the presence of DNA damage, can lead to mitotic 
catastrophe and ultimately cell death [22, 23]. As a result 
of this mechanism of action, WEE1 inhibitors have entered 
clinical trials as chemo-sensitizers of various tumors, such 
as breast cancer, leukemia and melanoma [24]. Previous 
Figure 3: Drug potency validation studies revealed (A) Ryuvidine to be selective against HPV-negative cell lines (** p=0.003) and 
(B) MK-1775 to be selective against HPV-positive cell lines (* p=0.03).
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studies have shown that MK-1775 can sensitize both HPV-
positive and HPV-negative cell lines to cisplatin therapy, 
but through differing mechanisms; senescence [25] versus 
apoptosis [26] in HPV-negative and HPV-positive cell lines, 
respectively. Our validation study revealed MK-1775 to 
be independently potent in reducing cellular proliferation, 
with preferential activity in HPV-positive cell lines (Figure 
3B). WEE1 kinase inhibition has been shown to selectively 
sensitize p53-deficient cells to exogenous DNA damage 
[25], and the higher susceptibility of HPV-positive cell lines 
to MK1775 may be due to the inhibition of p53 by the HPV 
E6 protein [27]. Further studies may be indicated to explore 
the potential of MK1775 compound as an HPV-specific 
chemotherapeutic agent.
Preliminary dose-response curve validation 
studies were able to validate the selectivity of 2 of the 6 
tested compounds that were derived based on our high-
throughput study. This is not surprising as the high-
throughput study included only a single dose of each 
compound, with the purpose of preliminary identification 
of compounds with potential for further assessment. 
More of the identified compounds may show HPV-status 
specific activity against HNSCCs following validation. 
Furthermore, analyses of the available HNSCC cell lines 
have revealed common genetic alterations other than 
HPV-status that are also reflected in tumor populations 
[28]. These include amplifications in PIK3CA, EGFR and 
CCND2, deletions in CDKN2A, SMAD4 and NOTCH2, 
and mutations in TP53, CDKN2A, SMAD4 and PIK3CA 
[28]. Thus, the genetic characterization of our cell line 
panel paired with our high-throughput drug screen can 
potentially be used to identify genomic correlates of drug 
response as a further step towards providing personalize 
medicine for head and neck cancer patients.
High-throughput testing of large chemical 
compound libraries can serve as valuable resources in the 
context of a necessity for better chemotherapeutics in the 
field of head and neck oncology. In this study, we have 
provided the head and neck cancer research community 
with the results of a preliminary screen of the activity 
of over 1400 compounds against 26 HNSCC cell lines. 
Initial validation studies led to the identification of 
Ryuvidine and MK-1775 compounds to have preferential 
activity against HPV-negative and HPV-positive cell lines 
respectively. We hope that the provided datasets can serve 
as a valuable resource to lay the foundation for further 
investigation of compounds with therapeutic potential in 
the field of head and neck oncology.
MATERIALS AND METHODS
Cell lines and culture conditions
Twenty-eight HNSCC cell lines were obtained 
from established culture collections or from collaborators 
as listed in Supplementary Table 5. Short tandem repeat 
profiling was carried out as previously described [29] and 
compared to the literature to confirm the cell line identity 
(Supplementary Table 6). Cells were cultured in an 
incubator at 37°C with 5% CO2 in the medium specified 
in Supplementary Table 5.
High-throughput drug screening
A custom-made compound library from Tocris 
Bioscience comprised of 1,113 compounds and a kinase 
inhibitor library of 320 compounds were used for high 
throughput drug screening. The drug screen was carried 
out against 6 HPV-positive and 20 HPV-negative cell lines 
(Supplementary Table 5). High-throughput drug studies 
were carried out in the S.M.A.R.T Facility in the Samuel 
Lunenfeld Research Institute at Mount Sinai Hospital in 
Toronto, Ontario, Canada. Cells were robotically seeded 
at a density of 600 cells/well in 384-well plates and 
incubated for 24 hours prior to the addition of drugs using 
an automated drug pinning device (Beckman Multimek, 
Mississauga, Ontario). Cells were treated with either DMSO 
(control) or a single dose of each drug at a concentration of 
4 μM, and cells were subsequently incubated for 48 hours 
based on methodology used in previous high-throughput 
studies [30, 31]. Cell viability was measured indirectly 
using the AlamarBlue reagent (ThermoFisher Scientific).
Statistical analysis
Fluorescence intensity derived from the high-
throughput screen were normalized using B scores as per 
recommendation of Malo et. al. [32]. For cell lines with 
two replicates, the average B score per drug was calculated. 
In each of the drug panels, the most potent drugs were 
identified as those with an average B score below -2. 
Drugs were then sorted based on the highest B score to the 
lowest within that stratification scheme. To identify drugs 
with preferential activity based on HPV-status, Student’s t-
tests were utilized to compare the average B score of HPV-
positive cell lines to that of HPV-negative cell lines for 
each drug. These p-values were then controlled for local 
false discovery rates using the fdrtool package version 
1.2.15 [33] in the R statistical environment (version 3.4.0). 
The statistical comparison was considered significant if the 
corrected p-value after correction by local false discovery 
rate (LFDR) was lower than 0.05. Drugs with significant 
preferential activity were then isolated by having a B score 
of lower than -2 in one disease type (ie HPV+ or HPV-) 
and a B score of higher than -2 in the opposite disease 
type, then sorted by the mean difference in the two arms of 
comparison (from high to low).
Generation of dose response curves
Six drugs (Ryuvidine, MK-1775, SNS-032, 
Flavopiridol, AZD-7762 and ARP-101) that demonstrated 
high differential activity in either HPV-positive or 
negative cell lines and mechanisms of action that were 
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deemed to be interesting in HNSCC were selected for 
further analysis. Dose response curves were generated, 
and drug validation studies for these compounds were 
tested in 8 HPV-positive and 11 HPV negative cell lines 
(cell lines listed in Supplementary Table 5). Cells were 
seeded in 96-well plates at 3000 cells/well. After 24 hours 
compounds were added in a concentration series of 0.01, 
0.03, 0.1, 0.3, 1, 3, 10, 30 and 100 μM. Three technical 
replicates were carried out in each cell line, per drug. 
Cells were incubated with the added drugs for 72 hours 
before assessing potency. Cell viability was measured 
indirectly using the PrestoBlue® Reagent (Thermofisher 
Scientific). To calculate the half-maximal inhibitory 
concentration (IC50) value for each cell line, normalized 
Relative Fluorescence Units (RFUs) of the drug-treated 
replicates were calculated as a percentage of the mean 
RFU of the vehicle control (DMSO-only) treatment 
replicates. IC50 values, defined as the concentration at 
which the normalized RFU reached 50%, were calculated 
by non-linear regression (Prism® 7 Graphpad Software, 
Inc). When a non-linear regression model could not be 
converged for a compound and cell line, no IC50 value was 
assigned and data was excluded from comparison analysis. 
An unpaired t-test was used to assess the significance of 
the differences in IC50 values between HPV-positive and 
HPV-negative cell lines for each of the compounds, and 
a p value of less than 0.05 was set as the significance 
limit. As a preliminary assessment of compound toxicity, 
we also tested 4 of the compounds (MK1775, Ryuvidine, 
AZD7762 and Flavopiridol) against the IMR90 non-
cancerous cell line (ATCC CCL-186) over a dose range of 
0.03 μM to 10 μM with the same methodology to generate 
dose-response curves and calculate IC50 values.
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